Embecta announced that it has submitted a 510(k) premarket filing to the U.S. FDA for a proprietary disposable insulin delivery system.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EMBC:
- embecta to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
- Embecta: FDA safety notice has no impact on any embecta syringe products
- embecta to Participate in Investor Conferences
- Embecta reports Q4 adjusted EPS 59c, consensus 40c
- Embecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance
